FTSE MIB
33.987,67 -118,34 (-0,35%) Dow Jones
39.375,87 +67,87 (+0,17%) Nasdaq
18.352,76 +164,46 (+0,90%) Nikkei 225
40.912,37 -1,28 (-0,00%) Petrolio
83,44 -0,44 (-0,52%) Bitcoin EUR
52.604,79 +1.188,14 (+2,31%)
CLSD Jan 2025 2.500 call
| Chiusura precedente | 0,0600 |
| Aperto | 0,0600 |
| Denaro | 0,1000 |
| Domanda | 0,5000 |
| Prezzo d'esercizio | 2,50 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 0,0600 - 0,0600 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 12 |
GlobeNewswireClearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial Enrollment is On Track with Data Expected in Q3 2024 - ALPHARETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial wer
- GlobeNewswire
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced that Arctic Vision, Clearside’s partner, has successfully completed enrollment in its Phase 3 randomized, double-blind, placebo-controlled clinical tri
- GlobeNewswire
Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit
ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Charles A. Deignan, Chief Financial Officer, will participate in a panel discussion at the JonesTrading 2023 Healthcare Summit. The panel, entitled, All About Eyes: Paradigm Shifting Therapeutic Innovations in Ophthalmology will take place on October
